drugset
drugset / Trial / NCT05724693

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

NCT05724693 ↗

Phase 1 Completed 39 enrolled Atea Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose

Timeline

Start
2023-01-30
Primary completion
2024-04-23
Completion
2024-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified — —

Indications

No indication recorded.